RYTMHealthcare · BiotechnologyThe 19 Wall Street analysts covering Rhythm Pharmaceuticals, Inc. hold a median 12-month price target of $143 — +60.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 87 of 100 as at 24 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Rhythm Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (89): Analysts have, on balance, been raising their forecasts.
Growth (47): Sales and profits are flat, shrinking, or growing more slowly than they were.
Size (20): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on RYTM, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +60.3% from it.
Of the 20 most recent actions, 7 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 16 Oct 2026 | William Blair | Initiates | Outperform | — |
| 15 Oct 2026 | JP Morgan | Maintains | Overweight | $146 → $145 |
| 12 Oct 2026 | HC Wainwright & Co. | Maintains | Buy | $105 → $130 |
| 8 Oct 2026 | RBC Capital | Maintains | Outperform | $155 → $159 |
| 8 Oct 2026 | RBC Capital | Maintains | Outperform | — |
| 14 Sept 2026 | Leerink Partners | Assumes | Outperform | $133 |
| 28 Aug 2026 | Deutsche Bank | Initiates | Hold | — |
| 28 Aug 2026 | Deutsche Bank | Initiates | Hold | $120 |
| 7 Aug 2026 | JP Morgan | Maintains | Overweight | $145 → $146 |
| 7 Aug 2026 | JP Morgan | Maintains | Overweight | — |
| 5 Aug 2026 | Citigroup | Maintains | Buy | $142 → $143 |
| 5 Aug 2026 | Citigroup | Maintains | Buy | — |
| 5 Aug 2026 | Citizens | Maintains | Market Outperform | $155 → $160 |
| 5 Aug 2026 | Citizens | Maintains | Market Outperform | — |
| 5 Aug 2026 | RBC Capital | Maintains | Outperform | $141 → $155 |
| 5 Aug 2026 | RBC Capital | Maintains | Outperform | — |
| 27 July 2026 | JP Morgan | Initiates | Overweight | $145 |
| 27 July 2026 | JP Morgan | Initiates | Overweight | — |
| 7 July 2026 | RBC Capital | Maintains | Outperform | — |
| 7 July 2026 | RBC Capital | Maintains | Outperform | $137 → $141 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
RYTM appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 23 Oct 2026, Rhythm Pharmaceuticals, Inc. returned −18.3% against +14.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 97% of US stocks
Cheaper than 7% of US stocks
Cheaper than 2% of US stocks
Cheaper than 92% of US stocks
Higher than 85% of US stocks
Higher than 73% of US stocks
Higher than 95% of US stocks
Higher than 15% of US stocks
Higher than 7% of US stocks
Higher than 12% of US stocks
Higher than 13% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Rhythm Pharmaceuticals, Inc. has a market value of $6.1B and an enterprise value of $6.0B.
Revenue in the twelve months to 30 June 2026: $239.9M. The latest quarter grew 46.9% year on year.
Net income over the same four quarters: −$205.3M, a −85.6% net margin.
Diluted earnings per share, trailing twelve months: $−3.11.
Free cash flow in the twelve months to 30 June 2026: −$106.3M.
Trailing P/E: −28.7×; forward P/E: −142.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Rhythm Pharmaceuticals, Inc. employs 414 people — $580K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Rhythm Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Rhythm Pharmaceuticals announced it will report its third-quarter 2026 financial results and provide a corporate update during a live conference call and webcast at 8:00 a.m. ET on Tuesday, November 3, 2026.
Why it matters — RYTM watchers can follow the scheduled results and corporate update for information about the company’s third quarter.
Rhythm Pharmaceuticals announced the commercial launch of IMCIVREE (setmelanotide) in Japan for patients with acquired hypothalamic obesity. The launch follows MHLW approval and the drug’s inclusion on Japan’s National Health Insurance drug price list.
Why it matters — The launch makes IMCIVREE the first approved therapy in Japan for acquired hypothalamic obesity, a development relevant to RYTM’s commercial activity.
Rhythm Pharmaceuticals (RYTM) was upgraded to Zacks Rank #2 (Buy), reflecting growing optimism about its earnings prospects. The excerpt says this optimism might drive the stock higher in the near term.
Why it matters — RYTM watchers may note the upgrade as a sign of increased optimism about the company's earnings prospects.
Rhythm Pharmaceuticals announced that Health Canada has approved IMCIVREE (setmelanotide) for the additional indication of weight management in adult and pediatric patients aged 4 years and older with acquired hypothalamic obesity (HO).
Why it matters — This regulatory approval expands the potential market for Rhythm Pharmaceuticals' IMCIVREE into a new indication and geography, broadening its commercial opportunity for RYTM watchers.
Rhythm Pharmaceuticals presented at the Morgan Stanley 24th Annual Global Healthcare Conference, and a transcript of the presentation was published by Seeking Alpha. The company participated in the conference as part of its investor outreach.
Why it matters — The presentation gives RYTM watchers direct insight into the company's current business update and management commentary delivered at a major healthcare investment conference.
The 19 Wall Street analysts covering Rhythm Pharmaceuticals, Inc. have a median 12-month price target of $143, with estimates ranging from $120 to $160. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 19 analysts covering Rhythm Pharmaceuticals, Inc., 17 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Rhythm Pharmaceuticals, Inc. 87 out of 100 across roughly 4,600 US stocks as at 24 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 24 Oct 2026, Rhythm Pharmaceuticals, Inc. ranks 87 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (89 of 100).
No one can know that. What the data says: the median 12-month target from 19 analysts implies +60.3% from the last close, and Ticker Nerd's factor model ranks Rhythm Pharmaceuticals, Inc. 87 out of 100 as at 24 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Rhythm Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RYTM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $120 to $160 over the next 12 months.
Rhythm Pharmaceuticals, Inc. returned -18.3% over the 12 months to 23 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare neuroendocrine diseases.
The most recent item we track (GlobeNewsWire, 21 Oct 2026): "Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026". Rhythm Pharmaceuticals announced it will report its third-quarter 2026 financial results and provide a corporate update during a live conference call and webcast at 8:00 a.m. ET on Tuesday, November 3, 2026.
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare neuroendocrine diseases. The company’s lead product, IMCIVREE (setmelanotide), is a precision medicine used to treat severe obesity and hyperphagia associated with specific melanocortin-4 receptor pathway disorders and acquired hypothalamic obesity. Rhythm Pharmaceuticals serves patients with serious rare conditions that are often underserved by conventional obesity treatments, and its work centers on targeted treatments designed for defined genetic and clinical populations. Based in Boston, Massachusetts, and founded in 2008, the company operates within specialty medicine, where it addresses unmet needs in rare metabolic and endocrine diseases through approved therapies and ongoing clinical development.
CEO Dr. David P. Meeker M.D. · 414 employees · United States · https://rhythmtx.com
